NGM’s NASH drug passes biomarker test but misses liver scarring endpoint

Bay Area biotech NGM Biopharmaceuticals reported Thursday afternoon that its drug candidate for non-alcoholic steatohepatitis, or NASH, improved results on a liver biomarker blood test in patients with the most severe form of the disease. But the results come after NGM Bio decided in 2021 against running a pivotal trial…

...

Click to view original post